PBS Calendars

Page last updated: 14 December 2018

PBS related activities surrounding the PBAC meeting cycles

If you are considering applying to have a drug listed on the PBS, it is recommended that you contact the Office of Health Technology Assessment (OHTA) to discuss the listing steps. If you are unsure of the most appropriate person to contact, the Industry Liaison Officer will be able to assist.

All contact details are available from the PBS contacts page.

PBAC Cycle Timeframe for 2018 - 2019

Week Activity

PBAC Cycle
2018/2

Meeting Date:
4-6 July

PBAC Cycle
2018/3

Meeting Date:
31 Oct-2 Nov

PBAC Cycle
2019/1

Meeting Date:
13-15 Mar

PBAC Cycle
2019/2

Meeting Date:
10-12 July

PBAC Cycle
2019/3

Meeting Date:
6-8 Nov

0

Deadline for major submissions (Wednesday)

7 Mar 2018

4 July 2018

31 Oct 2018

13 Mar 2019

10 July 2019

1

2

3

4

5

Submissions to discussants (Wednesday)

11 April 2018

8 Aug 2018

5 Dec 2018

17 Apr 2019

14 Aug 2019

5

Pre submission meetings with companies
(future submissions only)

9 Apr – 4 May 2018

6 Aug – 31 Aug 2018

3 Dec – 4 Jan 2019
(25, 26 Dec, 1 Jan PH)

15 Apr – 10 May 2019
(19, 22, 25 Apr PH)

12 Aug – 6 Sept 2019

6

Deadline for minor submissions (including Secretariat listings) (Friday)

20 Apr 2018

17 Aug 2018

14 Dec 2018

26 Apr 2019

23 Aug 2019

7

Publication of PBAC agenda on PBS website (Wednesday)

27 Apr 2018

22 Aug 2018

19 Dec 2018

1 May 2019

28 Aug 2019

7

Consumer Comments open

27 Apr 2018

22 Aug 2018

19 Dec 2018

1 May 2019

28 Aug 2019

8

9

10

Major submission commentaries to “Responsible Persons” (Wednesday)

16 May 2018

12 Sept 2018

23 Jan 2019

22 May 2019

18 Sept 2019

11

“Responsible Persons” send Pre-Subcommittee Responses to PBAC Secretariat (by midday Wednesday)

23 May 2018

19 Sept 2018

30 Jan 2019

29 May 2019

25 Sept 2019

11

Pre submission meetings with companies
(future submissions only)

21-25 May 2018

17-21 Sept 2018

29 Jan – 1 Feb 2019
(28 Jan PH)

28-31 May 2019
(27 May PH)

23-27 Sept 2019

12

DUSC meeting (Thursday-Friday)

31 May-1 June 2018

27-28 Sept 2018

7-8 Feb 2019

6-7 June 2019

3-4 Oct 2019

13

ESC meeting (Monday-Tuesday)

4-5 June 2018

2-3 Oct 2018
(1 Oct PH)

11-12 Feb 2019

11-12 June 2019
(10 Jun PH)

8-9 Oct 2019
(7 Oct PH)

13

Closing date for online consumer comments

6 June 2018

3 Oct 2018

13 Feb 2019

12 June 2019

9 Oct 2019

14

ATAGI meeting (Thursday – Friday)

14-15 June 2018

11-12 Oct 2018

21-22 Feb 2019

20-21 June 2019

17-18 Oct 2019

15

Minor submission overviews, ESC (major submissions only), DUSC (selected major submissions only), & ATAGI (vaccine
submissions only) advice & summary of consumer comments to “Responsible Persons” (Wednesday)

20 June 2018

17 Oct 2018

27 Feb 2019

26 June 2019

23 Oct 2019

16

“Responsible Persons” send Pre-PBAC Responses to PBAC Secretariat (by midday Wednesday)

27 June 2018

24 Oct 2018

6 Mar 2019

3 July 2019

30 Oct 2019

16

Pre submission meetings with companies not relating to imminent submissions (future submissions only)

25-29 June 2018

22-26 Oct 2018

4-8 Mar 2019

1-5 July 2019

28 Oct – 1 Nov 2019

17

PBAC meeting Wednesday-Friday

4-6 Jul 2018

31 Oct-2 Nov 2018

13-15 Mar 2019

10-12 July 2019

6-8 Nov 2019

17

(Close for next cycle major submissions on Wednesday)

4 Jul 2018

31 Oct 2018

13 Mar 2019

10 July 2019

6 Nov 2019

18

POST PBAC PROCEDURES:

19

20

Ratified Minutes (positive recommendations) to “Responsible Persons” (Friday)

27 Jul 2018

23 Nov 2018

5 Apr 2019

2 Aug 2019

29 Nov 2019

21

22

Ratified Minutes (all other recommendations) to “Responsible Persons” (Friday)

10 August 2018

7 Dec 2018

19 Apr 2019

16 Aug 2019

13 Dec 2019

23

Posting of recommendations on website following sponsor’s comments*
(Friday)

17 August 2018

14 Dec 2018

26 Apr 2019

23 Aug 2019

13 Dec 2019

23

Post-PBAC meetings with PBAC Chair
(Tue-Wed)

14-15 Aug 2017

11-12 Dec 2018

23-24 Apr 2019

20-21 Aug 2019

17-18 Dec 2019

24

Deadline for Independent Review requests for reconsideration at the meeting following the next meeting
(Friday)

24 August 2018

21 Dec 2018

3 May 2019

30 Aug 2019

2 Jan 2020

25

26

27

Draft PSDs  to “Responsible Persons”
(Friday)

14 Sept 2018

18 Jan 2019

24 May 2019

20 Sept 2019

24 Jan 2020

28

29

30

31

32

Finalisation of PSDs (Friday)

19 Oct 2018

22 Feb 2019

28 June 2019

25 Oct 2019

28 Feb 2020

33

PSDs published on web site (positives & subsequent rejections)
(Friday)

26 Oct 2018

1 March 2019

5 July 2019

1 Nov 2019

6 Mar 2020

0

1

PSDs published on web site (1st time rejections & deferrals)
(Friday)

9 Nov 2018

15 March 2019

19 July 2019

15 Nov 2019

20 Mar 2020

PBAC = Pharmaceutical Benefits Advisory Committee
“responsible persons” = legal wording requirement for terminology – previously known as sponsors
DUSC = Drug Utilisation Sub Committee    
ESC = Economic Sub Committee
ATAGI = Australian Technical Advisory Group on Immunisation
PSDs = Public Summary Documents
TBC = To be Confirmed
    
*  These dates may vary based on the number of submissions received    

Accessibility

The documents on this page may not be accessible. If you need help please contact HTA compliance (secretariat.compliance@health.gov.au).

Suitable Dates for Sponsors to meet with the Office of Health Technology Assessment (OHTA)

It is quite routine for sponsors to meet with relevant officers in the OHTA prior to submitting to the PBAC, however, the available opportunities for these meetings is limited by busy periods within the PBAC meeting cycle when key personnel have other priorities.

The weeks in the cycles assigned for OHTA-Sponsor meetings can be found in the PBAC Cycle Timeframe Calendar.

Please complete and return the meeting request form (Word 23 KB) to HTA compliance (secretariat.compliance@health.gov.au).

Once your request form has been received and reviewed by the OHTA a Departmental officer will be in touch to arrange a meeting time.

If the item to be discussed is a co-dependent technology sponsors must first contact the Health Technology Assessment (HTA) team (hta@health.gov.au) to arrange a joint meeting.

Health technologies are co-dependent if their use needs to be combined (either sequentially or simultaneously) to achieve or enhance the intended clinical effect of either technology.  For example, a drug/test combination where a new medicine seeking listing on the PBS may have a related pathology test that helps to determine the population group for that medicine.

Further information about the HTA processes can be found on the Department of Health website.